253 related articles for article (PubMed ID: 22721004)
1. Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib).
Fei F; Lim M; Schmidhuber S; Moll J; Groffen J; Heisterkamp N
Mol Cancer; 2012 Jun; 11():42. PubMed ID: 22721004
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
Gontarewicz A; Balabanov S; Keller G; Colombo R; Graziano A; Pesenti E; Benten D; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
Blood; 2008 Apr; 111(8):4355-64. PubMed ID: 18268096
[TBL] [Abstract][Full Text] [Related]
3. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.
Balabanov S; Gontarewicz A; Keller G; Raddrizzani L; Braig M; Bosotti R; Moll J; Jost E; Barett C; Rohe I; Bokemeyer C; Holyoake TL; Brümmendorf TH
PLoS One; 2011 Apr; 6(4):e19164. PubMed ID: 21541334
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cells.
Illert AL; Seitz AK; Rummelt C; Kreutmair S; Engh RA; Goodstal S; Peschel C; Duyster J; von Bubnoff N
PLoS One; 2014; 9(11):e112318. PubMed ID: 25426931
[TBL] [Abstract][Full Text] [Related]
5. Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias.
Fei F; Stoddart S; Groffen J; Heisterkamp N
Mol Cancer Ther; 2010 May; 9(5):1318-27. PubMed ID: 20388735
[TBL] [Abstract][Full Text] [Related]
6. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
Gontarewicz A; Balabanov S; Keller G; Panse J; Schafhausen P; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
Leuk Res; 2008 Dec; 32(12):1857-65. PubMed ID: 18514829
[TBL] [Abstract][Full Text] [Related]
7. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
[TBL] [Abstract][Full Text] [Related]
8. Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model.
Yuan H; Wang Z; Zhang H; Roth M; Bhatia R; Chen WY
Carcinogenesis; 2012 Feb; 33(2):285-93. PubMed ID: 22116466
[TBL] [Abstract][Full Text] [Related]
9. PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines.
Ultimo S; Simioni C; Martelli AM; Zauli G; Evangelisti C; Celeghini C; McCubrey JA; Marisi G; Ulivi P; Capitani S; Neri LM
Oncotarget; 2017 Apr; 8(14):23213-23227. PubMed ID: 28390196
[TBL] [Abstract][Full Text] [Related]
10. Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies.
Akahane D; Tauchi T; Okabe S; Nunoda K; Ohyashiki K
Cancer Sci; 2008 Jun; 99(6):1251-7. PubMed ID: 18429956
[TBL] [Abstract][Full Text] [Related]
11. Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor.
Gontarewicz A; Brümmendorf TH
Recent Results Cancer Res; 2010; 184():199-214. PubMed ID: 20072840
[TBL] [Abstract][Full Text] [Related]
12. Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.
Wang LX; Wang JD; Chen JJ; Long B; Liu LL; Tu XX; Luo Y; Hu Y; Lin DJ; Lu G; Long ZJ; Liu Q
Sci Rep; 2016 Nov; 6():35533. PubMed ID: 27824120
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.
Borthakur G; Dombret H; Schafhausen P; Brummendorf TH; Boissel N; Jabbour E; Mariani M; Capolongo L; Carpinelli P; Davite C; Kantarjian H; Cortes JE
Haematologica; 2015 Jul; 100(7):898-904. PubMed ID: 25887498
[TBL] [Abstract][Full Text] [Related]
14. Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
Ren X; Pan X; Zhang Z; Wang D; Lu X; Li Y; Wen D; Long H; Luo J; Feng Y; Zhuang X; Zhang F; Liu J; Leng F; Lang X; Bai Y; She M; Tu Z; Pan J; Ding K
J Med Chem; 2013 Feb; 56(3):879-94. PubMed ID: 23301703
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
Xiao X; Liu P; Li D; Xia Z; Wang P; Zhang X; Liu M; Liao L; Jiao B; Ren R
J Hematol Oncol; 2020 Jun; 13(1):80. PubMed ID: 32552902
[TBL] [Abstract][Full Text] [Related]
16. The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib.
Kelly KR; Ecsedy J; Medina E; Mahalingam D; Padmanabhan S; Nawrocki ST; Giles FJ; Carew JS
J Cell Mol Med; 2011 Oct; 15(10):2057-70. PubMed ID: 21091633
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
18. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
[TBL] [Abstract][Full Text] [Related]
19. Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia.
Mu C; Wu X; Ma H; Tao W; Zhang G; Xia X; Shen J; Mai J; Sun T; Sun X; Arlinghaus RB; Shen H
Mol Cancer Ther; 2016 May; 15(5):899-910. PubMed ID: 26846820
[TBL] [Abstract][Full Text] [Related]
20. Establishment of a new Philadelphia chromosome-positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation.
Okabe S; Tauchi T; Ohyashiki K
Exp Hematol; 2010 Sep; 38(9):765-72. PubMed ID: 20471447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]